DCLK1 and neoplasm: One blood-based biomarker that has been assessed in OAC is lymphocyte telomere length, which appears to correlate with risk of disease progression12, as has the presence of the putative tumour stem cell marker Doublecortin Like Kinase 1 (DCLK1) in the serum of OAC patients13.